Marc Ceulemans

Head of Strategic Venture Capital Fund, Pharma Equities at Novartis AG

Marc Ceulemans

Marc Ceulemans

Head of Strategic Venture Capital Fund, Pharma Equities at Novartis AG

Biography

Marc Ceulemans is on the board of Seventh Sense Biosystems, Inc.

Overview
RelSci Relationships

1146

Number of Boards

1

Relationships
RelSci Relationships are individuals Marc Ceulemans likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Pulmatrix, Inc. (Inactive)

Relationship likelihood: Strong

President & Director at Neurovia, Inc.

Relationship likelihood: Strong

Chairman & President at Advanced Accelerator Applications SA

Relationship likelihood: Strong

Co-Founder at Seventh Sense Biosystems, Inc.

Relationship likelihood: Strong

Chief Executive Officer & President at Seventh Sense Biosystems, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Novartis AG

Relationship likelihood: Strong

Co-Founder at C4 Therapeutics, Inc.

Relationship likelihood: Strong

Venture Partner at Novartis Venture Fund

Relationship likelihood: Strong

Chief Executive Officer, Sandoz at Novartis AG

Relationship likelihood: Strong

Auditor at Novartis Venture Fund

Relationship likelihood: Strong

In The News
peHUB
November 18, 2016
7SBio bags $10 mln Series C
Paths to Marc Ceulemans
Potential Connections via
Relationship Science
You
Marc Ceulemans
Head of Strategic Venture Capital Fund, Pharma Equities at Novartis AG
Career History
Head of Strategic Venture Capital Fund, Pharma Equities
Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head of Strategic Venture Capital Fund, Pharma Equities
Current

NVF is an active venture capital investor focused exclusively on life sciences. They contribute financially as well as by taking Board positions. They seek initial early-stage investments to develop, nurture and support innovative therapeutics. They balance these investments with those in medical devices, diagnostics and drug delivery systems, areas critical to patient care and the healthcare industry.NVF's early-stage investments are also complemented by their follow-on investment rounds leading to more advanced unlisted firms within the life sciences sector. Investment criteria include looking for unmet needs, clinical impact and new proprietary science. Investments are made in North America, Europe, and Switzerland and in Asia/Pacific.The Novartis Option Fund is designed to provide an alternative financing vehicle. The investment focus is on financing during the earliest stages of start-up firms that are developing novel technologies and programs which may ultimately contribute to Novartis' own research projects. The fund's strategy is high risk / high return.

Boards & Committees
Member, Board of Directors
2016 - Current

Seventh Sense Biosystems, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Marc Ceulemans. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Marc Ceulemans's profile does not indicate a business or promotional relationship of any kind between RelSci and Marc Ceulemans.